Use of the dopamine agonist cabergoline in the treatment of movement disorders

Author： Di Marco Aimee Appiah-Kubi Linda S Chaudhuri K Ray

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.3, Iss.10, 2002-10, pp. : 1481-1487

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of Dopamine Agonist Pergolide in Outpatient Treatment of Cocaine Dependence

By A. Focchi G. Leite M. Andrade A. Scivoletto S.

Substance Use & Misuse, Vol. 40, Iss. 8, 2005-07 ,pp. : 1169-1177

Informa Healthcare

Access to resources Recommend Favorite

Dopamine D4 Receptor Antagonists for the Treatment of Cocaine Use Disorders

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 14, Iss. 6, 2015-08 ,pp. : 707-715

Bentham Science Publishers

Access to resources Recommend Favorite

Cabergoline: A Review of its Use in the Treatment of Parkinson's Disease

By Monique P. Curran Caroline M. Perry

Drugs, Vol. 64, Iss. 18, 2004-01 ,pp. : 2125-2141

Adis International

Access to resources Recommend Favorite

The Long-Acting Dopamine Receptor Agonist Cabergoline in Early Parkinsons Disease: Final Results of a 5-Year, Double-Blind, Levodopa-Controlled Study

By Fulvio Bracco

CNS Drugs, Vol. 18, Iss. 11, 2004-01 ,pp. : 733-746

Adis International

Access to resources Recommend Favorite

Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes

By Scranton Richard Cincotta Anthony

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 269-279

Informa Healthcare

Access to resources Recommend Favorite